Supriya Lifescience has received the Establishment Inspection Report (EIR) for its manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, indicating ‘Voluntary Action Indicated' (VAI), signifying a successful completion of the inspection.
The United States Food and Drug Administration (USFDA) conducted an inspection at the company’s manufacturing facility located at Lote from February 02, 2026 to February 06, 2026. The inspection concluded with the issuance of a Form 483 containing one minor observation. The company has adequately addressed the observation.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: